Watch the CEO Signature Series interview with Jan-Anders Karlsson, CEO of Verona Pharma (VRNA).
Jan-Anders Karlsson, CEO
Biography:
Jan-Anders Karlsson, PhD, has served as Verona Chief Executive Officer and on the Company’s board of directors since June 2012. Prior to his time at Verona, he was CEO of S*BIO Pte Ltd, a biotechnology company in Singapore, from 2005 to 2012, and before that he served as Executive Vice President and head of Pharma Global Research at Bayer Healthcare AG in Germany. Dr. Karlsson received a M.Sc. in pharmacy from Uppsala University and a Doctor of Medical Science (Ph.D.) in clinical experimental pharmacology from the University of Lund.
Company Description:
Verona Pharma's lead product candidate, RPL554, is a first-in-class inhaled compound with both bronchodilator and anti-inflammatory effects and is being investigated for the treatment of chronic obstructive pulmonary disease and cystic fibrosis, two debilitating respiratory diseases with significant gaps in current treatment options for patients.
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for the treatment of respiratory diseases with significant unmet medical needs. Verona Pharma's product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has been observed to result in statistically significant improvements in lung function as compared to placebo and has shown clinically meaningful and statistically significant improvements in lung function when added to two commonly used bronchodilators as compared to either bronchodilator administered as a single agent. Verona Pharma is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and potentially asthma.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
